Time to Move to Targeted Drugs in Biliary Tract Cancer?

Christophe Louvet\textsuperscript{a,b} Christophe Tournigand\textsuperscript{a}

\textsuperscript{a} Service d' oncologie, hôpital St-Antoine, 
\textsuperscript{b} Université Pierre et Marie Curie (Paris VI), Paris, France

Biliary tract cancers comprise a large variety of anatomic situations: intrahepatic cholangiocarcinomas, extrahepatic cholangiocarcinomas, adenocarcinomas of the gallbladder and of ampulla of Vater. Even if they have different prognoses, and require different surgical procedures when resectable, they are often together considered in clinical trials of chemotherapy for advanced disease. Unfortunately, the majority of patients presents with unresectable disease at diagnosis, and overall prognosis remains very poor.

The use of chemotherapy in advanced biliary cancers (ABC) was justified by the Glimelius study [1], where palliative chemotherapy demonstrated a survival and a quality of life advantage as compared to best supportive care. Quality of biliary drainage remains a key prognostic factor, and must be the first goal to achieve before starting chemotherapy. Until recently, ABC were considered as orphan diseases, and a lot of small non randomized studies based on various drugs and combined treatments have been published. A review of the literature (112 trial arms and 2,810 patients) confirmed the value of several national guidelines: single-agent antimitabolites (gemcitabine or 5 fluorouracil) are more active than any other single drugs, and combined treatments of antimitabolite + platinum salt are more active than single agents or any other combined treatment [2], the more promising combinations being gemcitabine + cisplatin and gemcitabine + oxaliplatin [3, 4]. This was later confirmed this year by one Japanese randomized phase II study [5] and especially by one UK randomized phase III study [6], which found a significant advantage in terms of overall survival for this combination compared to gemcitabine alone. This UK study not only defined a new standard of care, but also demonstrated that it is now feasible to perform large-scale studies in ABC.

Targeted therapies are now widely used in oncology, and definitively represent a new step in the therapeutic advances. Despite the definition of a new standard of care in ABC, prognosis remains very poor with a median survival of less than a year, and this warrants to test targeted therapies in this disease. To date, no consistent data concerning ABC and antiangiogenic drugs is available, and very few concerning ABC and anti EGFR (epidermal growth factor receptor) drugs. In this issue of \textit{Onkologie}, Chang and collaborators [7] report 5 cases of patients with ABC and treated with cetuximab combined with modulated fluorouracil, either as first- or as second-line treatment. All 5 patients showed disease control (1 CR, 3 PR and 1 SD). Activity of anti EGFR in ABC was previously reported in two cases (PR achieved in first line using gemcitabine + cetuximab [8]; PR achieved in first line using radiation therapy combined with cetuximab [9]), and in a series of 9 patients resistant to gemcitabine + oxaliplatin (1 CR, 1 PR and 1 SD out of the 9 patients) after addition of cetuximab to GEMOX at progression [10]. Results of a prospective phase II study using GEMOX + cetuximab as first-line treatment for 30 ABC patients were reported during the past ASCO 2009, with an impressive 63.3% response rate and a 12.7 months median survival [11]. At the same time, preliminary results of a French-German randomized study (GEMOX with or without cetuximab) have been reported, with a promising increase in progression-free survival (PFS) for the combined arm [12].

It is now well demonstrated that efficacy of EGFR antibodies is related to tumoral K-RAS wild-type status and not to EGFR expression in colon cancer [13]. Therefore, EGFR antibodies should be restricted to a sub-population of patients. This may not be the case in other types of tumor, and relationships between EGFR antibodies activity and K-RAS mutational status have to be further explored. EGFR overexpression is strongly correlated with tumor progression in ABC [14]. K-RAS tumor mutations have been reported in ABC, at various rates depending on the geographic origin of the patients as well as on the primary tumor location: reported mu-
tations rate ranged from 0 to 50% in Asian patients [15, 16] and from 12 to 54% in patients from western countries [11, 17]; in gallbladder, ampulloma and extrahepatic cholangiocarcinomas, such mutations seem to be absent or very infrequent [18]. Considering the poor prognosis of gallbladder cancers treated with conventional chemotherapy, these findings are to be taken into account. Interestingly, neither progression-free survival nor overall survival were affected by K-RAS status in the GEMOX + cetuximab phase II study [11].

Regarding the poor prognosis of ABC despite the recent definition of a standard of care, improvements of results are urgently needed. Antiangiogenic drugs deserve to be tested. The use of EGFR inhibitors appears as a promising option. However, this should be done through well conducted prospective clinical trials, with companion biological explorations, in order to better understand the optimal place of such drugs in ABC.

References


Targeted Drugs in Biliary Tract Cancer

Oncology 2010;33:10–11

11